image credit: Unsplash

A serial biotech entrepreneur launches his next startup with high-dollar backing

December 7, 2021


Gary Glick, a chemist and well-known biotech entrepreneur, has raised more than $200 million to launch the latest company aiming to harness advances in medicinal chemistry to invent new drugs for cancer and inflammatory diseases.

Called Odyssey Therapeutics, the startup is backed by OrbiMed Advisors, SR One Capital Management and half a dozen other venture capital firms that collectively staked Glick and his team with the sizable Series A financing round.

For now, Odyssey isn’t revealing much about the diseases or targets it hopes to go after, although its funding has allowed the company to sketch out seven drug discovery programs.

Read More on Biopharma Dive